O le Helio Health, o se kamupani fa'alesoifua maloloina e fa'atautaia e le AI o lo'o taula'i i le fa'atauina o su'esu'ega vave e iloa ai le kanesa mai se su'ega toto faigofie, i aso nei na fa'asalalauina ai e le Hepatology Communications na lomia fa'ai'uga lelei mai le su'esu'ega ENCORE e fa'amaonia ai le malosi o le falema'i a HelioLiver i le su'esu'eina o le i ai o le tino o le hepatocellular carcinoma (HCC). , o le ituaiga sili ona taatele o le kanesa o le ate ma le lona fitu o le kanesa sili ona taatele i le lalolagi atoa ae o le lona lua i le kanesa e aafia ai le oti, e masani lava ona o le tuai o suʻesuʻega.1 I lenei suʻesuʻega faʻamoemoe, tauaso, tele-center Phase 2, na faʻaalia e HelioLiver le maualuga maualuga (91). %) ma le maualuga maaleale (76%) i le suʻeina vave-laasaga (laasaga I ma II) HCC, e matua sili atu nai lo isi mea faigaluega faʻapitoa e maua ile falemaʻi e pei ole AFP (57%), GALAD (65%), ma le ultrasound (47%). 2,3 Pe a iloiloina le HCC atoa, na faia HelioLiver i le 85% lagona ma le tutusa 91% specificity.2
| Su'ega Su'ega HCC | Laasaga Amata (I + II) Ma'ale'ale | Ma'ale'ale Aotele |
| HelioLiver2 | 76% | 85% |
| AFP (≥ 20 ng/mL)2 | 57% | 62% |
| Sikoa GALAD (≥ -0.63)2 | 65% | 75% |
| Faatulagaga3 | 47% | 84% |
| Fa'aaliga: O le laulau e fa'aalia ai lagona maaleale o HelioLiver ile 91% fa'apitoa2 | ||
| 2 Lin N, et al. 2021. | ||
| 3 Tzartzeva K, et al. 2018. |
Na fausia e Helio lona fa'asologa o fa'asologa fa'asologa, ECLIPSETM, e fa'ailoa 77 methylation fa'atatau ile 28 genes. O nei faʻailoga DNA e galulue faʻatasi ma le serum HCC proteins AFP, AFP-L3%, ma le DCP e faʻaleleia ai le algorithm multi-analyte.
• O le vaega o lo'o i lalo o le fa'aogaina o uiga (AUROC) mo HelioLiver o le 0.944, o lo'o fa'aalia ai le sili atu le lelei o le va'aiga i lo isi su'ega.
• I se tulaga fa'apitoa o le 87.5%, na ausia e HelioLiver le 87% le maaleale mo le amataga o le HCC ma le 90% fa'alogona lautele.
• O le 10 o le 28 genes na faʻaaogaina i le suʻega HelioLiver na maua saʻo aʻafia i auala mole mole e iloa e aʻafia i le HCC pathogenesis ae naʻo le tasi o suʻesuʻega ae leʻi filifilia 497 genes na ausia tulaga tutusa, ma fautua mai o faʻailoga i HelioLiver e sili atu. e fa'atatau i mea ola nai lo su'ega e fa'aogaina ai isi kenera.
Hepatology Communications o le faʻasalalauga faʻasalalau aloaʻia, suʻesuʻeina e tupulaga a le American Association for the Study of Liver Diseases (AASLD), faʻapitoa i le faʻasalalau vave o suʻesuʻega maualuga i le hepatology. AASLD o le faʻalapotopotoga faʻapitoa faʻafomaʻi taʻiala mo faʻamaʻi ate i le Iunaite Setete.
HelioLiver o loʻo faʻaauau le suʻesuʻega e avea o se vaega o le suʻesuʻega faʻapitoa a le biomarker a Helio, CLiMB (NCT03694600), lea o le a faʻatusatusa saʻo ai le faʻatinoga o le suʻega i le ultrasound e faʻaaoga ai le tele-phasic MRI e avea ma tulaga o le tausiga o le HCC suʻesuʻega.
OA MEA E AVEA MAI LENEI TUSI:
- Helio Health, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced that Hepatology Communications published positive results from the ENCORE study validating HelioLiver’s strong clinical performance in detecting the presence of early hepatocellular carcinoma (HCC), the most common form of liver cancer and the seventh most common cancer worldwide but the second in cancer-related mortality, often due to late diagnosis.
- 10 of the 28 genes used in the HelioLiver test were found to be directly involved in molecular pathways known to be implicated in HCC pathogenesis while only one of the investigated but unselected 497 genes met the same criteria, suggesting that the markers in HelioLiver are more biologically relevant than tests that utilize these other genes.
- HelioLiver o loʻo faʻaauau le suʻesuʻega e avea o se vaega o le suʻesuʻega faʻapitoa a le biomarker a Helio, CLiMB (NCT03694600), lea o le a faʻatusatusa saʻo ai le faʻatinoga o le suʻega i le ultrasound e faʻaaoga ai le tele-phasic MRI e avea ma tulaga o le tausiga o le HCC suʻesuʻega.
